Eary J F, Press O W, Badger C C, Durack L D, Richter K Y, Addison S J, Krohn K A, Fisher D R, Porter B A, Williams D L
Department of Radiology, University of Washington Medical Center, Seattle.
J Nucl Med. 1990 Aug;31(8):1257-68.
Ten patients with non-Hodgkin's lymphoma have been evaluated as candidates for experimental radioimmunotherapy and five of those patients have been treated with a single high dose of iodine-131-(131I) labeled anti-pan B-cell antibodies. The evaluation protocol involved collecting biodistribution data by quantitation of gamma camera images and by tumor biopsy from trace labeled doses of antibody, to estimate the relative radiation dose delivered to normal organs and tumor sites. Each patient received up to three escalating mass doses (0.5 mg/kg, 2.5 mg/kg, and 10.0 mg/kg) of radioiodinated antibody for determination of the antibody amount that yielded the most favorable biodistribution for treatment. The millicuries of 131I-labeled to the optimal antibody dose for therapy was selected to deliver 1,000 rads (three patients) or 1,500 rads (two patients) to normal uninvolved organs. Because severe bone marrow toxicity was expected, all patients had their bone marrow cryopreserved prior to entry into the study. This report details the methods and results of quantitative imaging, biodistribution data collection, and absorbed radiation dose estimation in patients with lymphoma receiving high level radioimmunotherapy with 131I-labeled antibodies.
十名非霍奇金淋巴瘤患者被评估为实验性放射免疫治疗的候选对象，其中五名患者接受了单次高剂量的碘 - 131（¹³¹I）标记的抗全B细胞抗体治疗。评估方案包括通过对γ相机图像进行定量分析以及从微量标记剂量的抗体进行肿瘤活检来收集生物分布数据，以估计传递到正常器官和肿瘤部位的相对辐射剂量。每位患者接受高达三个递增质量剂量（0.5 mg/kg、2.5 mg/kg和10.0 mg/kg）的放射性碘化抗体，以确定产生最有利治疗生物分布的抗体量。选择标记到最佳治疗抗体剂量的¹³¹I毫居里数，以便向未受累的正常器官传递1000拉德（三名患者）或1500拉德（两名患者）。由于预期会出现严重的骨髓毒性，所有患者在进入研究前均对其骨髓进行了冷冻保存。本报告详细介绍了接受¹³¹I标记抗体的高水平放射免疫治疗的淋巴瘤患者的定量成像方法、生物分布数据收集以及吸收辐射剂量估计的方法和结果。
